Fiche centre
Hiroshima University Hospital
Hiroshima — Japan
Essais liés10clinical trials
VilleHiroshimalocalisation
PaysJapanlocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05716100
Essais cliniques associés
10| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| XEN1101 | Épilepsie | Phase 3 | NCT05716100 | A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) | RECRUITING |
| ZL-1310 | Cancer | Phase 3 | NCT07218146 | A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE) | RECRUITING |
| Inavolisib | Cancer | Phase 3 | NCT06790693 | INAVO123 — A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer | RECRUITING |
| MT-1186 | Sclérose latérale amyotrophique | Phase 3 | NCT05151471 | Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS | TERMINATED |
| M5049 low dose | Lupus | Phase 2 | NCT05540327 | The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE) | ACTIVE_NOT_RECRUITING |
| Cenerimod | Lupus | Phase 3 | NCT05648500 | OPUS-1 — A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus | ACTIVE_NOT_RECRUITING |
| Nipocalimab | Myasthénie | Phase 3 | NCT04951622 | A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis | RECRUITING |
| Litifilimab | Lupus | Phase 3 | NCT05352919 | EMERALD — A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION |
| Pembrolizumab | Parkinson | Phase 3 | NCT03358472 | Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) | COMPLETED |
| Efgartigimod PH20 SC | Myasthénie | Phase 3 | NCT06558279 | ADAPT oculus — A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis | ACTIVE_NOT_RECRUITING |